Generation Bio

Generation Bio EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Generation Bio (GBIO) as of Nov 10, 2026 is -142.39 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -138.56 M USD — a change of 2.76% (lower).

EBITDA

-142.39 MUSD

YoY

2.76%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Generation Bio is 2024 -142.39 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Generation Bio was 2023 -138.56 M USD. It decreases by 2.76% lower compared to the previous year.

The Generation Bio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-37.29 M USD
Jan 1, 2019
-62.30 M USD
Jan 1, 2020
-81.11 M USD
Jan 1, 2021
-119.10 M USD
Jan 1, 2022
-141.18 M USD
Jan 1, 2023
-138.56 M USD
Jan 1, 2024
-142.39 M USD
The Generation Bio EBITDA history
YEAREBITDAYoY
-142.39 MUSD+2.76%
-138.56 MUSD-1.86%
-141.18 MUSD+18.54%
-119.10 MUSD+46.83%
-81.11 MUSD+30.19%
-62.30 MUSD+67.06%
-37.29 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Generation Bio Stock analysis

What does Generation Bio do? Generation Bio Co. is a genetic medicines company headquartered in Cambridge, Massachusetts, that focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The firm is developing a class of gene therapy utilizing its non-viral gene therapy platform to deliver genetic payloads to a range of tissues. The company’s non-viral gene therapy platform includes its DNA construct called closed-ended DNA (ceDNA), its cell-targeted lipid nanoparticle delivery system (ctLNP) and its established, scalable capsid-free manufacturing process. The firm is engineering its gene therapies to be redosable, which enable patient titration to reach the desired therapeutic expression and to maintain efficiency in a patient’s life. The firm is a preclinical stage company and have not identified a product candidate. Generation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Generation Bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Generation Bio is -142.39 M USD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Generation Bio changed from -138.56 M USD to -142.39 M USD, representing a 2.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Generation Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Generation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Generation Bio

All Key Metrics — Generation Bio